AI Slashes Drug Discovery Time by 75% as UAE Lab Unveils Third Cancer Candidate This Year
Insilico Medicine's artificial intelligence platforms have identified novel blood cancer molecules in 12-18 months, a process that traditionally takes up to four years, marking the company's third major therapeutic announcement in six months.
AI-Designed Drug Reaches Landmark Phase III Trial for Fatal Lung Disease
Insilico Medicine's rentosertib becomes the first AI-developed therapeutic to enter late-stage testing for idiopathic pulmonary fibrosis, a condition with few treatment options and a median survival of just 3-4 years.
The First Fully AI-Designed Drug Reaches Phase 3 Trials—And Its Maker Is Already Profitable
Insilico Medicine's rentosertib marks a watershed moment for artificial intelligence in pharmaceutical development, advancing to large-scale human testing while the company reports $35.5 million in net profit.
Machine Learning Cracks the Mitochondrial Code: Five New Drug Targets Emerge for Alzheimer's Treatment
Insilico Medicine's AI platform identifies blood-detectable biomarkers and novel therapeutic pathways by analyzing mitochondrial dysfunction across multiple neurodegenerative diseases.
The Patent Paradox Threatening Billions in AI-Discovered Drugs
As artificial intelligence designs novel therapeutics with minimal human input, U.S. patent law's human-inventor requirement is creating legal uncertainty that could invalidate exclusivity rights for an entire generation of AI-developed medicines.
Drug Discovery's New Speed Limit: How AI Slashed a Decade-Long Process to 18 Months
Insilico Medicine's breakthrough pulmonary fibrosis candidate reached Phase 2 trials in record time, forcing clinical operators to rethink procurement, trial partnerships, and patient engagement strategies.
AI Platform Delivers Eye Drop Candidate That Triples Efficacy Against Leading Cause of Vision Loss
Insilico Medicine's generative chemistry AI produces ISM9077 in half the traditional timeline, targeting dry AMD and inflammatory eye diseases with superior preclinical performance.
The $8.9 Billion Question: Why AI Drug Discovery Still Has Nothing on Pharmacy Shelves
Three years of sliding approval timelines expose a critical gap between artificial intelligence's preclinical promise and the regulatory infrastructure needed to bring AI-discovered medicines to patients.
AI Drug Discovery Firm Lands Second $177M Deal in 90 Days as Platform Monetization Accelerates
Insilico Medicine's rapid-fire partnerships with China Medical System signal a pivotal shift from AI platform development to commercial-stage drug discovery, with CNS target identified entirely by generative algorithms.
Building the AI-Native Health System: The Chief Health AI Officer's Mandate
As artificial intelligence reshapes the healthcare landscape, the Chief Health AI Officer emerges as the critical bridge between technological innovation and clinical excellence.
Big Pharma Bets Big on AI: Takeda Partners with Insilico to Reinvent Drug Discovery Pipeline
Major pharmaceutical company taps generative AI platform to slash development timelines and identify novel drug candidates across multiple therapeutic areas.